A study presented at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting in Washington, DC, investigated the potential survival benefit associated with the addition of androgen deprivation therapy (ADT) to radiation therapy (RT) in older patients with prostate cancer. Dr. Timothy Dougherty and colleagues from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, compared the risk of mortality among patients with intermediate-risk prostate cancer who were age 60 or older. Overall, 10,168 men received RT plus ADT and 12,396 received RT alone. A larger proportion of men in the RT plus ADT group had Gleason 4+3 ...